Arkansas and interim Coach Bobby Petrino have some familiarity with Texas A&M second-year offensive coordinator Collin Klein, ...

And why the Glen Powell character barely beats Eli’s alma mater Ole Miss on the series, but torches Peyton Manning’s Tennessee Volunteers. By Tony Maglio Eli Manning had one final gift to give to Chad ...

As Hulu’s official Episode 3 synopsis explains, “It’s the second half of the season opener against Ole Miss and the Catfish ...

It’s weird to see Nintendo hardware holding its own rather than fighting for its life against more powerful alternatives. For now, at least, the Switch 2 feels more than just “good enough.” ...

Eli Manning always had an unserious side to his personality. He just thought it was wise not to show it while playing for the New York Giants. “I was always very fearful or careful that if I got too ...

Eli Lilly's shares have increased by about 10% over the past month. Clinical progress in the past few weeks has helped solidify its lead in the weight loss market. The company's prospects remain ...

IN recent months makers of weight-loss drugs have gone on a crash diet. In late July Novo Nordisk, the Danish firm that gave the world Ozempic, lost a quarter of its market value in a day after it cut ...

The pharmaceutical company Eli Lilly announced on Tuesday that it will build a $6.5 billion facility in Texas, marking the company’s second multibillion-dollar U.S. investment this month. The ...

Colts quarterback Daniel Jones has plenty of history with the Mannings. Enough to joke around with Peyton and Eli on ESPN’s “The Manningcast” on Monday night, making his appearance in the second ...

Eli Lilly (LLY) remains a strong growth company, driven by leadership in the booming GLP-1 and diabetes drug markets despite recent share price weakness. LLY's aggressive investments in manufacturing, ...

LONDON, Sept 24 (Reuters) - Eli Lilly (LLY.N), opens new tab Chief Executive Dave Ricks said Britain was "probably the worst country in Europe" for drug prices in an interview with the Financial Times ...

Eli Lilly has won the second FDA approval for an oral selective estrogen receptor degrader (SERD). Like the first oral SERD, Lilly’s imlunestrant is only cleared to treat ER-positive, HER2-negative ...